Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

CAR T-cells in autoimmunity: game changer or stepping stone?

Dimitrios Mougiakakos, Everett Meyer, Georg Schett

Blood blood.2024025413.

https://doi.org/10.1182/blood.2024025413

Published: 2024

Includes: Supplemental data

Journal Articles

CD47 Upregulation Inhibits Phagocytic Clearance of Alloreactive Donor T Cells after Allo-HCT

Haroon Shaikh, Cindy Flamann, Carina Matos, Hla Ali, Michael AG Kern, Marina Kreutz, Maike Buettner-Herold, Christopher Lischer, Simon Voelkl, Christian Kellner, Katrin Bitterer, Domenica Saul, Ernst Holler, Alma Zernecke, Dimitrios Mougiakakos, Andreas Beilhack, Heiko Bruns

Blood (2024) 144 (Supplement 1): 2023.

https://doi.org/10.1182/blood-2024-205870

Published: 2024

Journal Articles

Update on Monocentric CD19-CAR T-Cell Therapy in 30 Patients with Autoimmune Disease

Blood (2024) 144 (Supplement 1): 684.

https://doi.org/10.1182/blood-2024-206163

Published: 2024

Journal Articles

Deciphering Inflammasome Activation in Gaucher Macrophages and Its Role in the Development of Multiple Myeloma

Vivien Reinecke, Daniel Hofbauer, Jörg-Thomas Bittenbring, Christopher Lischer, Johannes Berges, Gina Nusser, Katrin Bitterer, Simon Voelkl, Dimitrios Mougiakakos, Andreas Mackensen, Heiko Bruns

Blood (2024) 144 (Supplement 1): 1153.

https://doi.org/10.1182/blood-2024-203108

Published: 2024

Journal Articles

A Study on Experimentally Induced Thrombus Formation in JAK2-V617F and Calr-del52 Mouse Models Using Ligation of the Inferior Vena Cava (IVC)

Vikas Bhuria, Martin Böttcher, Vanja Zeremski, Andreas Müller, Dimitrios Mougiakakos, Thomas Fischer

Blood (2024) 144 (Supplement 1): 4521.

https://doi.org/10.1182/blood-2024-210931

Published: 2024

Journal Articles

Real-World Evidence of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, Lenalidomide with or without Polatuzumab (VIPOR(P)) for Relapsed/Refractory Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 6494.

https://doi.org/10.1182/blood-2024-200002

Published: 2024

Journal Articles

Anti-CD37 CAR T cells: another arrow in the quiver

Dimitrios Mougiakakos

Blood (2024) 144 (11): 1133–1134.

https://doi.org/10.1182/blood.2024025361

Published: 2024

Journal Articles

CD19-Targeted CAR-T Cells in Refractory Systemic Autoimmune Diseases: A Monocentric Experience from the First Fifteen Patients

Blood (2023) 142 (Supplement 1): 220.

https://doi.org/10.1182/blood-2023-180547

Published: 2023

Journal Articles

Proteomic Profiling and Cytokine Analysis Reveals Molecular Signatures and Inflammatory Factors Associated with Thrombosis in JAK2-V617F Positive Myeloproliferative Neoplasm (MPN) Cohorts

Vikas Bhuria, Marco van Ham, Katrin Vogel, Ana Waldleben, Vanja Zeremski, Martin Böttcher, Monika Brunner-Weinzierl, Dimitrios Mougiakakos, Burkhart Schraven, Lothar Jänsch, Thomas Fischer

Blood (2023) 142 (Supplement 1): 6340.

https://doi.org/10.1182/blood-2023-174835

Published: 2023

Journal Articles

JAK2-V617F Promotes up-Regulation of Pro-Inflammatory Cytokines Including IL-1 upon Adhesion-Induced Activation of β1/β2 Integrins

Conny K. Baldauf, Emmanouil Charakopoulos, Martin Böttcher, Vanja Zeremski, Dimitrios Mougiakakos, Burkhart Schraven, Thomas Fischer

Blood (2023) 142 (Supplement 1): 2749.

https://doi.org/10.1182/blood-2023-174058

Published: 2023

Journal Articles

Blocking the CD47-Sirpa Axis Enhances Tafasitamab-Mediated Phagocytosis

Blood (2022) 140 (Supplement 1): 9292–9293.

https://doi.org/10.1182/blood-2022-159955

Published: 2022

Journal Articles

Early Real Time Quantification of CD19. CAR T Cells By Flow Cytometry As a Predictive Biomarker for Response in Patients with R/R LBCL

Blood (2022) 140 (Supplement 1): 7522–7523.

https://doi.org/10.1182/blood-2022-168874

Published: 2022

Journal Articles

CD19-Targeted CAR-T Cells in Refractory Systemic Lupus Erythematosus: Safety, Efficacy, and Mechanistic Insights from the First Five Patients

Fabian Mueller, Simon Voelkl, Dimitrios Mougiakakos, Sebastian Boeltz, Michael Aigner, Regina Gary, Sascha Kretschmann, Soraya Kharboutli, Arnd Kleyer, David Simon, Wolf Rösler, Katharina M. Habenicht, Thomas H. Winkler, Gerhard Krönke, Georg Schett, Andreas Mackensen

Blood (2022) 140 (Supplement 1): 4562–4563.

https://doi.org/10.1182/blood-2022-165077

Published: 2022

Journal Articles

GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany

Blood (2022) 140 (4): 349–358.

https://doi.org/10.1182/blood.2021015209

Published: 2022

Includes: Supplemental data

Journal Articles

CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma

Blood (2021) 138 (24): 2499–2513.

https://doi.org/10.1182/blood.2020010543

Published: 2021

Includes: Supplemental data

Journal Articles

Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia

Hardikkumar Jetani, Almudena Navarro-Bailón, Marius Maucher, Silke Frenz, Christina Verbruggen, Ana Yeguas, María Belén Vidriales, Marcos González, Judit Rial Saborido, Sabrina Kraus, Katrin Mestermann, Simone Thomas, Halvard Bonig, Maik Luu, Razieh Monjezi, Dimitrios Mougiakakos, Markus Sauer, Hermann Einsele, Michael Hudecek

Blood (2021) 138 (19): 1830–1842.

https://doi.org/10.1182/blood.2020009192

Published: 2021

Includes: Supplemental data

Journal Articles

Late Non-Relapse Mortality (NRM) after Standard-of-Care (SOC) CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Frequency, Causes, and Risk Factors.a GLA/DRST Real World Analysis

Blood (2021) 138 (Supplement 1): 1748.

https://doi.org/10.1182/blood-2021-151469

Published: 2021

Journal Articles

The CAR-Hematotox Identifies Patients at High Risk for Prolonged Neutropenia, Infectious Complications and Prolonged Hospitalization Following CD19-CART in R/R LBCL

Blood (2021) 138 (Supplement 1): 3852.

https://doi.org/10.1182/blood-2021-149579

Published: 2021

Journal Articles

Standard of Care CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Does Bridging Efficacy Matter? a German GLA/DRST Real World Analysis

Blood (2021) 138 (Supplement 1): 3822.

https://doi.org/10.1182/blood-2021-146120

Published: 2021

Journal Articles

Polatuzumab Vedotin in Relapsed and Refractory (r/r) Large B-Cell Lymphoma (LBCL): Real-World Data of the German National Compassionate Use Program (CUP)

Blood (2020) 136 (Supplement 1): 11–13.

https://doi.org/10.1182/blood-2020-136539

Published: 2020

NARROW

CAR T-cells in autoimmunity: game changer or stepping stone?

CD47 Upregulation Inhibits Phagocytic Clearance of Alloreactive Donor T Cells after Allo-HCT

Update on Monocentric CD19-CAR T-Cell Therapy in 30 Patients with Autoimmune Disease

Deciphering Inflammasome Activation in Gaucher Macrophages and Its Role in the Development of Multiple Myeloma

A Study on Experimentally Induced Thrombus Formation in JAK2-V617F and Calr-del52 Mouse Models Using Ligation of the Inferior Vena Cava (IVC)

Real-World Evidence of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, Lenalidomide with or without Polatuzumab (VIPOR(P)) for Relapsed/Refractory Large B-Cell Lymphoma

Anti-CD37 CAR T cells: another arrow in the quiver

CD19-Targeted CAR-T Cells in Refractory Systemic Autoimmune Diseases: A Monocentric Experience from the First Fifteen Patients

Proteomic Profiling and Cytokine Analysis Reveals Molecular Signatures and Inflammatory Factors Associated with Thrombosis in JAK2-V617F Positive Myeloproliferative Neoplasm (MPN) Cohorts

JAK2-V617F Promotes up-Regulation of Pro-Inflammatory Cytokines Including IL-1 upon Adhesion-Induced Activation of β1/β2 Integrins

Blocking the CD47-Sirpa Axis Enhances Tafasitamab-Mediated Phagocytosis

Early Real Time Quantification of CD19. CAR T Cells By Flow Cytometry As a Predictive Biomarker for Response in Patients with R/R LBCL

CD19-Targeted CAR-T Cells in Refractory Systemic Lupus Erythematosus: Safety, Efficacy, and Mechanistic Insights from the First Five Patients

GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany

CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma

Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia

Late Non-Relapse Mortality (NRM) after Standard-of-Care (SOC) CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Frequency, Causes, and Risk Factors.a GLA/DRST Real World Analysis

The CAR-Hematotox Identifies Patients at High Risk for Prolonged Neutropenia, Infectious Complications and Prolonged Hospitalization Following CD19-CART in R/R LBCL

Standard of Care CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Does Bridging Efficacy Matter? a German GLA/DRST Real World Analysis

Polatuzumab Vedotin in Relapsed and Refractory (r/r) Large B-Cell Lymphoma (LBCL): Real-World Data of the German National Compassionate Use Program (CUP)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only